-
2025-523769-11-00
5
2026-04-30
Overweight
-
2024-519830-22-00
5
2026-04-27
Heart failure due to systemic left ventricular systolic dysfunction
-
2025-522867-13-00
4
2026-04-27
Non Small Cell Lung Cancer
-
2024-514006-31-00
9
2026-04-16
Non-active Progressive Multiple Sclerosis (PMS)
-
2025-523803-31-00
4
2026-04-16
Advanced non-small cell lung cancer (NSCLC)
-
2025-521521-33-00
10
2026-04-02
Kidney transplant rejection
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2024-512436-29-00
11
2026-03-27
CARDIOVASCULAR DISEASES
-
2025-523204-68-00
4
2026-03-25
HER2-positive breast cancer
-
2025-520467-40-00
9
2026-03-16
High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in
-
2025-522492-28-00
4
2026-03-13
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis,
-
2025-523202-32-00
5
2026-02-26
Major Depressive Disorder
-
2025-522553-19-00
10
2026-02-25
Symptomatic genetic and familial dilated cardiomyopathy.
-
2024-520027-88-00
4
2026-02-12
Patients with hormone receptor-positive (HR+) breast cancer
-
2025-521919-39-00
3
2026-02-10
Resected stage IIB, IIC, or III melanoma requiring adjuvant treatment
-
2025-522398-12-00
3
2026-01-30
Locally advanced or metastatic NSCLC
-
2024-519706-13-00
6
2026-01-26
Patients with Stable or Unstable coronary syndromes who have undergone
-
2024-518936-36-00
6
2026-01-23
Active smokers
-
2025-521581-10-00
7
2026-01-16
Neoplasms, Prostate
-
2024-520337-80-00
5
2026-01-07
Palmoplantar Pustulosis
-
2025-521562-95-00
5
2025-12-30
Previously Untreated Advanced (Unresectable or Metastatic) Melanoma
-
2022-503140-41-00
5
2025-12-19
Melanoma
-
2023-505661-89-00
4
2025-12-19
Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
-
2024-510778-26-00
4
2025-12-19
Metastatic Non-Small-Cell Lung Cancer